Scarica l'app Stockscreener
56.75
1.58%
0.88
Dopo l'orario di chiusura:
56.94
0.19
+0.33%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVMD Giù?
Forum
Previsione
Precedente Chiudi:
$55.87
Aprire:
$55.62
Volume 24 ore:
2.46M
Relative Volume:
2.33
Capitalizzazione di mercato:
$9.32B
Reddito:
$29.52M
Utile/perdita netta:
$-484.27M
Rapporto P/E:
-17.41
EPS:
-3.26
Flusso di cassa netto:
$-457.88M
1 W Prestazione:
+12.55%
1M Prestazione:
+19.93%
6M Prestazione:
+41.17%
1 anno Prestazione:
+156.09%
Intervallo 1D:
$54.97
$56.91
Intervallo di 1 settimana:
$49.92
$56.91
Portata 52W:
$18.79
$56.91
Revolution Medicines Inc Stock (RVMD) Company Profile
Nome
Revolution Medicines Inc
Settore
Industria
Telefono
415-766-3638
Indirizzo
700 SAGINAW DR, REDWOOD CITY, CA
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-16 | Reiterato | Needham | Buy |
| 2024-07-12 | Iniziato | Barclays | Overweight |
| 2024-07-08 | Iniziato | Jefferies | Buy |
| 2024-04-12 | Reiterato | Needham | Buy |
| 2024-04-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-01-04 | Iniziato | Wedbush | Outperform |
| 2023-11-16 | Iniziato | Raymond James | Outperform |
| 2023-02-28 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-10-21 | Iniziato | Oppenheimer | Outperform |
| 2022-05-20 | Iniziato | BofA Securities | Neutral |
| 2022-03-01 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-08-12 | Downgrade | Goldman | Buy → Neutral |
| 2021-05-18 | Iniziato | Goldman | Buy |
| 2020-05-21 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-09 | Iniziato | Cowen | Outperform |
| 2020-03-09 | Iniziato | Guggenheim | Buy |
| 2020-03-09 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Revolution Medicines Inc Borsa (RVMD) Ultime notizie
Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year HighWhat's Next? - MarketBeat
Revolution Medicines to Participate in Upcoming Investor Conferences - The Manila Times
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Report Preview: What To Look For - GuruFocus.com
Revolution Medicines' SWOT analysis: cancer drug developer's stock potential - Investing.com India
Revolution Medicines' SWOT analysis: cancer drug developer's stock potential By Investing.com - Investing.com UK
Brokerage firm bumps Revolution Medicines stock PT on positive trial data - Investing.com Canada
Revolution Medicines (NASDAQ:RVMD) Given New $60.00 Price Target at Oppenheimer - Defense World
Revolution Medicines (RVMD) Set to Announce Earnings on Wednesday - MarketBeat
Allspring Global Investments Holdings LLC Raises Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024 - The Manila Times
Revolution Medicines stock hits 52-week high at $51.01 - Investing.com
Revolution Medicines stock hits 52-week high at $51.01 By Investing.com - Investing.com UK
Raymond James & Associates Purchases 116,135 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
China Universal Asset Management Co. Ltd. Purchases 12,744 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines (NASDAQ:RVMD) PT Raised to $82.00 - MarketBeat
Revolution Medicines Targets Hard-to-Treat Pancreatic Cancer With Two Early-Phase Readouts - BioSpace
Revolution Medicines reports positive RMC-9805 study results - Investing.com India
Revolution Medicines reports positive RMC-9805 study results By Investing.com - Investing.com Australia
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma - The Manila Times
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with - The Bakersfield Californian
Revolution Medicines Presents Initial Data from RMC-9805 - GlobeNewswire
Needham & Company LLC Reaffirms Buy Rating for Revolution Medicines (NASDAQ:RVMD) - MarketBeat
(RVMD) On The My Stocks Page - Stock Traders Daily
Revolution Medicines reports progress in pancreatic cancer study By Investing.com - Investing.com Australia
Revolution Medicines (NASDAQ:RVMD) Shares Up 3.2%Still a Buy? - MarketBeat
Revolution Medicines reports progress in pancreatic cancer study - Investing.com India
Revolution Medicines Presents Updated Data from RMC-6236 - GlobeNewswire
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma - Yahoo Finance
Head to Head Comparison: Revolution Medicines (NASDAQ:RVMD) vs. Fresh Tracks Therapeutics (NASDAQ:FRTX) - Defense World
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma - BioSpace
Revolution Medicines Announces First Patient Dosed in Phase - GlobeNewswire
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Revolution Medicines executive sells $824,804 in stock - Investing.com India
Revolution Medicines executive sells $824,804 in stock By Investing.com - Investing.com South Africa
Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month HighTime to Buy? - MarketBeat
Insider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Sells 16,666 Shares of Stock - MarketBeat
Revolution Medicines COO Margaret Horn sells $2.52m in stock - Investing.com India
Revolution Medicines COO Margaret Horn sells $2.52m in stock By Investing.com - Investing.com South Africa
Revolution Medicines CEO sells $1.51 million in stock By Investing.com - Investing.com Australia
Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini Sells 6,000 Shares - MarketBeat
Revolution Medicines CFO Jack Anders sells shares worth $502,979 - Investing.com India
Revolution Medicines CFO Jack Anders sells shares worth $502,979 By Investing.com - Investing.com Australia
Revolution Medicines' general counsel sells $301,026 in stock By Investing.com - Investing.com Canada
Revolution Medicines CEO sells $1.51 million in stock - Investing.com India
Revolution Medicines' general counsel sells $301,026 in stock - Investing.com India
AQR Capital Management LLC Purchases New Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Check Out Revolution Medicines Inc (RVMD)’s Trade Data Rather Than the Analysts’ Views - SETE News
An Analysis of Revolution Medicines Inc (RVMD)’s Potential Price Growth - Knox Daily
Trend Tracker for (RVMD) - Stock Traders Daily
Revolution Medicines Inc Azioni (RVMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):